Chinese Journal of Dermatology ›› 2019, Vol. 52 ›› Issue (4): 223-230.doi: 10.3760/cma.j.issn.0412-4030.2019.04.001
• Guidelines and Consensus • Next Articles
Committee on Psoriasis, Chinese Society of Dermatology
Received:
2018-12-10
Revised:
2019-02-20
Online:
2019-04-15
Published:
2019-04-01
Contact:
Zhang Xuejun
E-mail:ayzxj@vip.sina.com
Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 simplified edition)[J]. Chinese Journal of Dermatology, 2019, 52(4): 223-230.doi:10.3760/cma.j.issn.0412-4030.2019.04.001
[1] | Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania[J]. Int J Dermatol, 1996,35(9):633⁃639. |
[2] | Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30⁃year follow⁃up of a population⁃based cohort[J]. Br J Dermatol, 2013,168(6):1303⁃1310. doi: 10.1111/ bjd.12230. |
[3] | Shao CG, Zhang GW, Wang GC. Distribution of psoriasis in China: a nationwide screening[J]. Proc Chin Acad Med Sci Peking Union Med Coll, 1987,2(2):59⁃65. |
[4] | 丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010,24(7):598⁃601. |
[5] | 中华医学会皮肤性病学分会银屑病学组. 中国银屑病治疗指南(2008版)[J]. 中华皮肤科杂志, 2009,42(3):213⁃214. doi: 10.3760/cma.j.issn.0412⁃4030.2009.03.030. |
[6] | 中华医学会皮肤性病学分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志,2014, 47(3):213⁃215. doi: 10.3760/cma.j.issn.0412⁃4030.2014.03.017. |
[7] | Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action[J]. J Cutan Med Surg, 2013,17(1):6⁃12. doi: 10.2310/7750.2012.11124. |
[8] | Koo J, Bandow G, Feldman SR, et al. The art and practice of UVB phototherapy for the treatment of psorasis//Weinstein GD, Gottlieb AB. Therapy of moderate⁃to⁃severe psorasis[M]. New York: Marcel Dekker, 2003:53⁃90. |
[9] | Bianchi B, Campolmi P, Mavilia L, et al. Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis⁃related molecules in psoriasis[J]. J Eur Acad Dermatol Venereol, 2003,17(4):408⁃413. |
[10] | Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308⁃nm excimer laser for treatment of psoriasis: results of a multicenter study[J]. J Am Acad Dermatol, 2002,46(6):900⁃906. |
[11] | Bagel J. Adalimumab plus narrowband ultraviolet B light photo⁃therapy for the treatment of moderate to severe psoriasis[J]. J Drugs Dermatol, 2011,10(4):366⁃371. |
[12] | Vidal D, Salleras M, Romaní J, et al. Adherence of self⁃administered subcutaneous methotrexate in patients with chronic plaque⁃type psoriasis[J]. J Eur Acad Dermatol Venereol, 2016,30(11):e131⁃e132. doi: 10.1111/jdv.13409. |
[13] | Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis[J]. J Rheumatol, 2014,41(6):1049⁃1060. doi: 10.3899/jrheum.130738. |
[14] | Cline A, Jorizzo JL. Does daily folic acid supplementation reduce methotrexate efficacy?[J/OL]. Dermatol Online J, 2017,23(11):6. pii: 13030/qt4hf5v2vk. |
[15] | Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate⁃associated safety and efficacy in inflammatory disease: a systematic review[J]. Br J Dermatol, 2009,160(3):622⁃628. doi: 10.1111/j.1365⁃2133.2008.08876.x. |
[16] | Ortiz Z, Shea B, Suarez⁃Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials[J]. J Rheumatol, 1998,25(1):36⁃43. |
[17] | Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis[J]. J Am Acad Dermatol, 1993,28(3):466⁃469. |
[18] | Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents[J]. J Am Acad Dermatol, 2009,61(3):451⁃485. doi: 10.1016/j.jaad.2009.03.027. |
[19] | Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta⁃analysis in 579 patients[J]. Am J Clin Dermatol, 2001,2(1):41⁃47. doi: 10.2165/00128071⁃200102010⁃00007. |
[20] | Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1⁃year multicentre, randomized study. The PISCES Study Group[J]. Br J Dermatol, 1999,141(2):283⁃291. |
[21] | Ho VC, Griffiths CE, Berth⁃Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long⁃term management of psoriasis: a 2⁃year cohort study[J]. J Am Acad Dermatol, 2001,44(4):643⁃651. doi: 10.1067/mjd.2001.112400. |
[22] | Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis[J]. J Am Acad Dermatol, 1998,39(3):464⁃475. |
[23] | Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis[J]. Health Technol Assess, 2000,4(40):1⁃125. |
[24] | Colombo D, Cassano N, Altomare G, et al. Psoriasis relapse evaluation with week⁃end cyclosporine A treatment: results of a randomized, double⁃blind, multicenter study[J]. Int J Immunopathol Pharmacol, 2010,23(4):1143⁃1152. doi: 10.1177/039463201002300418. |
[25] | Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I[J]. J Am Acad Dermatol, 2010,63(6):925⁃946; quiz 947⁃948. doi: 10.1016/j.jaad.2010.02.063. |
[26] | Pathirana D, Ormerod AD, Saiag P, et al. European S3⁃guidelines on the systemic treatment of psoriasis vulgaris[J]. J Eur Acad Dermatol Venereol, 2009,23 Suppl 2:1⁃70. doi: 10.1111/j.1468⁃3083.2009.03389.x. |
[27] | Gollnick HP. Oral retinoids⁃⁃efficacy and toxicity in psoriasis[J]. Br J Dermatol, 1996,135 Suppl 49:6⁃17. |
[28] | Ling MR. Acitretin: optimal dosing strategies[J]. J Am Acad Dermatol, 1999,41(3 Pt 2):S13⁃S17. |
[29] | Carretero G, Ribera M, Belinchón I, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology[J]. Actas Dermosifiliogr, 2013,104(7):598⁃616. doi: 10.1016/j.adengl.2013.01.001. |
[30] | Nast A, Gisondi P, Ormerod AD, et al. European S3⁃Guidelines on the systemic treatment of psoriasis vulgaris⁃⁃Update 2015⁃⁃Short version⁃⁃EDF in cooperation with EADV and IPC[J]. J Eur Acad Dermatol Venereol, 2015,29(12):2277⁃2294. doi: 10.1111/jdv.13354. |
[31] | Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis[J]. J Am Acad Dermatol, 2016,74(2):280⁃287. e1⁃e3. doi: 10.1016/j.jaad.2015.09.056. |
[32] | Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial[J]. Lancet, 2005,366(9494):1367⁃1374. doi: 10.1016/S0140⁃6736(05)67566⁃6. |
[33] | Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate⁃to⁃severe plaque psoriasis[J]. J Am Acad Dermatol, 2007,56(1):31. e1⁃e15. doi: 10.1016/j.jaad.2006.07.017. |
[34] | Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial[J]. J Am Acad Dermatol, 2008,58(1):106⁃115. doi: 10. 1016/j.jaad.2007.09.010. |
[35] | Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL[J]. J Am Acad Dermatol, 2012,66(2):241⁃251. doi: 10.1016/j.jaad.2010.12.005. |
[36] | Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 76⁃week results from a randomised, double⁃blind, placebo⁃controlled trial (PHOENIX 1)[J]. Lancet, 2008,371(9625):1665⁃1674. doi: 10.1016/S0140⁃6736(08)60725⁃4. |
[37] | Papp KA, Griffiths CE, Gordon K, et al. Long⁃term safety of ustekinumab in patients with moderate⁃to⁃severe psoriasis: final results from 5 years of follow⁃up[J]. Br J Dermatol, 2013,168(4):844⁃854. doi: 10.1111/bjd.12214. |
[38] | Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial[J]. J Am Acad Dermatol, 2015,73(3):400⁃409. doi: 10.1016/j.jaad. 2015.05.013. |
[39] | Lesner K, Reich A, Szepietowski JC, et al. Determinants of psychosocial health in psoriatic patients: a multi⁃national study[J]. Acta Derm Venereol, 2017,97(10):1182⁃1188. doi: 10. 2340/00015555⁃2760. |
[1] | Sun Xiaojie, Liu Yi. Anti-androgen drugs in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 56(9): 882-885. |
[2] | Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888. |
[3] | Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848. |
[4] | Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844. |
[5] | Chen Yaolong, Liu Hui, Yao Zhirong, Gao Xinghua. Strategies and suggestions for improving the quality of guidelines and consensus in the field of dermatology [J]. Chinese Journal of Dermatology, 2023, 56(9): 805-808. |
[6] | Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786. |
[7] | Zhong Jiemin, Shao Lei, Liang Yimin, Huang Qiongxiao, Xia Manqi, Liu Yumei. Comparative study on efficacy and safety of single microneedle radiofrequency versus photodynamic therapy in the treatment of inflammatory lesions of moderate to severe facial acne vulgaris [J]. Chinese Journal of Dermatology, 2023, 56(8): 751-755. |
[8] | Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723. |
[9] | Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802. |
[10] | Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen. Cell therapy for hereditary epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2023, 56(7): 698-702. |
[11] | Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692. |
[12] | Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650. |
[13] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
[14] | Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705. |
[15] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023)” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |
|